Trial purpose
Cancer treatment
Tumor type
Lower gastrointestinal tract
Age
18+
Clinical summary
Summary
Patients eligible to participate in this study will receive Trifluridine/tipiracil hydrochloride tablets to be taken 1 hour after morning and evening meals for 10 days in week 1 and 2 of a 4 week cycle, with Bevacizumab administered by IV on Day 1 and 15 of the four week cycle. In the Capecitabine + Bevacizumab arm of the study patients will receive Capecitabine tablets to be taken on days 1 to 14 of a three week cycle, with Bevacizumab administered on day 1 of each three week cycle.
Conditions
This trial is treating people with Metastatic Colorectal Cancer
Eligibility
Inclusion
- Has definitive histologically confirmed adenocarcinoma of the colon or rectum (all other histological types are excluded). Primary tumour localisation must be known.
- RAS status based on local biological assessment of tumour biopsy must be available. If RAS status is not available at the time of randomisation, tumour biopsy must be available for RAS status determination (based on local biological assessment).
- Patient is not a candidate for standard full dose combination chemotherapy with irinotecan or oxaliplatin
- Patient is not a candidate for curative resection of metastatic lesions.
- No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.
- ECOG (Eastern Cooperative Oncology Group) performance status ≤2.
-
Adequate organ function (renal, haematological, hepatic, coagulation) as described in the study protocol'
Exclusion
- Pregnancy, breastfeeding or possibility of becoming pregnant during the study.
- Participation in another interventional study within 4 weeks prior to the randomisation .
- Patients who have not recovered from clinically relevant non-hematologic CTCAE grade ≥ 3 toxicity of previous anticancer therapy prior to the randomisation.
- Symptomatic central nervous system metastases.
-
Major surgery within 4 weeks prior to the randomisation.
Exclusion criteria related to S 95005 administration:
- History of allergic reactions attributed to compounds of similar composition to S 95005 or any of its excipients.
-
Any contraindication present in the SmPC of trifluridine/tipiracil
Exclusion criteria related to bevacizumab administration:
-
Any contraindication present in the SmPC of bevacizumab
Exclusion criteria related to capecitabine administration:
- Any contraindication present in the SmPC of capecitabine
Inclusion
- You are able to swallow medication by mouth.
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
Exclusion
- You have had certain treatments, surgical procedures or drugs.
- You are currently being treated on a clinical trial.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
- NCT03869892 *
- CL3-95005-006, 2017-004059-22, U1111-1206-3198
Trial sponsor
Servier
Scientific Title
An Open-label, Randomised, Phase III Study comparing TrifLuridine/Tipiracil (S95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in first-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not candidate for Intensive Therapy
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information